Status:
UNKNOWN
Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
Lead Sponsor:
Medicines for Malaria Venture
Collaborating Sponsors:
Universidad Peruana Cayetano Heredia
UNITAID
Conditions:
Malaria, Vivax
Eligibility:
All Genders
6+ years
Brief Summary
The goal of this study is to evaluate the operational feasibility of using a new treatment algorithm for Malaria Vivax in Peru. The implementation package includes the following interventions: * A r...
Detailed Description
The goal of this study is to evaluate the operational feasibility of providing Tafenoquine and Primaquine after semi-quantitative G6PD testing at different levels of the health services, in order to i...
Eligibility Criteria
Inclusion
- Inclusion Criteria Health Care Providers:
- • All HCPs working in the selected facilities who are involved in the management of vivax patients.
- Inclusion criteria patients:
- All patients aged 6 months onward, who have a confirmed P. vivax infection and who are treated in a study Health Facilities
- Pregnant and lactating women, who have a contra-indication to both Primaquine and Tafenoquine, but for whom correct case management will be evaluated as part of the primary endpoints.
- Patients providing informed consent and/or informed assent
- Exclusion criteria patients:
- • Patients with signs of severe infection
Exclusion
Key Trial Info
Start Date :
August 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05361486
Start Date
August 28 2023
End Date
October 31 2024
Last Update
December 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nauta Nucleo- Base
Nauta, Loreto, Peru, 16310